Financial Disclosures
|
|
|
- Andrew Townsend
- 5 years ago
- Views:
Transcription
1 Financial Disclosures Consultant Genentech, Regeneron, Allergan, Thrombogenics, Optos, and ArcticDx Grant Support Regeneron, Allergan Mathew W. MacCumber, MD, PhD Professor & Assoc. Chair for Research Rush University Medical Center Chicago, IL Proliferative diabetic retinopathy (PDR) Proliferative vitreoretinopathy (PVR) Macular pucker & Macular hole Diabetic macular edema (DME) Vitreo-macular traction syndrome (VMT) Exudative age-related macular degeneration (AMD)? Vitrectomy is the current treatment vitreoretinal interface pathology Vitreomacular traction syndrome Macular hole Pharmacologic vitreolysis using microplasmin has demonstrated potential to induce PVD Rapid diffusion of drugs It s mostly water Has relatively few molecular components It s relatively acellular ILM Stain for Fibronectin Vitreous adhesion to ILM is mediated by: Fibronectin Laminin Chondroitin Glycoconjugates G. A. Williams, MD 1
2 G. Williams M. Trese Hydrolyzing laminin and fibronectin which bridge collagen fibers between the posterior vitreous cortex and the ILM Trese and Williams developed autologous plasmin method Induces PVD, especially in young patients, dose and duration dependent Cumbersome preparation using patients serum Kringle 4 (Fibrin binding site) Kringle 3 Kringle 2 Kringle 1 (Fibrin binding site) Kringle 5 Serine Protease (active part) 88 kda Size 29 kda Size Protein Ribbon Structure Generic name for microplasmin Lacks inactive kringle domains Direct-acting thrombolytic (unlike plasminogen activator) Smaller molecule, allows better retinal penetration Recombinant technology Induces PVD with single 75μg or 125μg injection ThromboGenics Leuven, Belgium ~ Dublin, Ireland ~ New York NY Injection The MIVI Trials MIcroplasmin for VItreous Injection 2
3 19 Centers 125 Patients without PVD Scheduled for Vitrectomy Sacramento Los Angeles Huntington Beach San Diego Tucson Data Monitoring Board Julia Haller, MD William Mieler, MD Lloyd-Paul Aiello, MD PhD Syracuse Boston Minneapolis Royal Oak Pittsburgh New York Chicago Cleveland New Brunswick Raleigh Houston Winter Haven Ft. Meyers McAllen Control Saline Injection 25μg Injection 75μg Injection 125μg Injection Phase IIb randomized, placebo-controlled, double-masked, parallel-group, dose-ranging US study Pars plana vitrectomy 7 days after injection Primary analysis after 35 days (full follow-up at 6 months) Posterior Vitreous Detachment Avoidance of Surgery V-M traction resolution Macular hole closure Assessed by a masked surgeon at the beginning of vitrectomy If vitrectomy not performed: Based on investigator assessment of OCT or B-Scan Safety Endophthalmitis Uveitis Retinal tears Vision Pre-injection - Baseline /63 3
4 Day 7 /5 Surgery Cancelled 1 month /32 Ophthalmology 1;117: Rate of total PVD noted at time of surgery: 1% vs. 125µg 31% VMT resolution at 35 days precluding need for surgery: 3% vs. 125µg 31% Macular hole closed without surgery at 35 days: % vs. 125µg 35% Design: Population: Allocation: Follow-Up: Randomized, placebo-injection controlled, double-masked trial (same for both studies) Symptomatic fvma (Patients with VMT or macular holes < μm) 125µg intravitreal injection vs. placebo (vehicle*) injection 2:1: MIVI 6 (US) 3:1: MIVI 7 (US & Europe) 6 months *Vehicle = Mannitol 3.75 mg/ml, Citric Acid Monohydrate 1.51 mg/ml Primary endpoint (MIVI-6 & -7): nsurgical resolution of fvma by Day 28 (determined by Central Reading Center [CRC]) Key Secondary endpoints (MIVI-6 & -7): Proportion of patients with total posterior vitreous detachment (PVD) at Day 28 (determined by ultrasound by investigators) Proportion of patients with nonsurgical closure of macular hole (determined by CRC) 23 Macular Condition Vitreo-Macular Traction Full Thickness Macular Hole (n=16) (n=2) 74 (69.8%) 163 (74.1%) 32 (3.2%) 57 (25.9%) 4
5 fvma Resolut9ion (%) fvma Resolut9ion (%) fvma Resolut9ion (%) 3/6/14 Ocular Characteristic (n=16) (n=2) Epiretinal Membrane 34 (32.1%) 87 (39.7%) Focal Vitreomacular Adhesion (fvma) diameter >15 μm 19 (17.9%) 47 (21.4%) % 1.2% 26.9% n = 187 n = % n = % n = % 8.% - ERM + ERM - ERM + ERM n = 113 n = 6 n = 26 n = % n = 16 % n = % 8.9% 15 µm > 15 µm 15 µm > 15 µm n = 74 n = 19 n = 143 n = 45 5
6 Patients, % fvma Resolut9ion (%) fvma Resolut9ion (%) 3/6/ %.6% % 13.3% % n = 187 n = 465 n = 47 n = 16 Optimization of Patient Selection and Expected Outcomes with Ocriplasmin Treatment Different Hole Types and Where to Measure CASE STUDIES: DIAMETER OF FTMH ( µm AND > µm) Baseline After Injection Day 7 After Injection Month 6 /5 /5 /25 < µm > µm Large FTMH, less resolution Source: openi.nlm.nih.gov Pharmacologic Closure of FTMH* at Day 28 by FTMH Width at Baseline 8 p<.1 Ocriplasmin p= * μm with VMA Data on file. ThromboGenics, Inc. 13. n= μm >25 to μm > μm N=
7 % Postop Hole Closure Rate (n) (n=19) (n=26) 84.2% (16) 84.6% (22) Adverse event (AE) % (n=17) (n=219) Any ocular AE Any ocular serious AE Vitreous floaters Photopsia Any Any ocular ocular Vitreous AE 55.1% 71.7% serious AE 1.3% 9.6% floaters 8.4% 19.2% Photopsia 3.7% 16.4% Conjunctival hemorrhage Eye pain Vision blurred Cataract Visual impairment MH Visual acuity reduced Photophobia 6.4 Retinal edema Anterior chamber cell IOP increase Metamorphopsia 4.1 % Retinal Break During 6 mo. Follow-up (n=17) (n=219) Any Retinal Tear or Retinal Detachment 3.74 % 3.19 % Intra / Post-Operative Retinal Tear or Detachment 3.74 % 2.28 % Retinal Tear Retinal Detachment 1.86 % 1.86 % 1.83 %.46 % n-operative Retinal Tear or Detachment %.91 % Retinal Tear Retinal Detachment % % %.91 % Verteporfin Therapy: All Trials Acute Severe VA Decrease Study TAP Investigation 1 VIP Trial 1 VAM 2 VIM 3 VER 4 JAT 4 VALIO 4 Total n/n % 3/2 1/225 33/4435 1/77 1/323 2/64 3/6 53/ TAP and VIP Study Groups. Am J Ophthalmol. 4;137: VAM Study Writing Committee. Retina. 4;24: VIM Study Group. Arch Ophthalmol. In press. 4. Data on file, vartis Pharma AG Prior Stroke CHF Arrhythmias Angioplasty Valve Malfunction Stroke Rate by Potential Risk Factor Rate (n/n) 2.7% (2/73) 9.6% (7/73).5% (6/196).7% (8/1136) 3.3% (2/6) 3.1% (2/65).5% (6/119) 1.1% (13/1144).5% (1/214) 3.5% (7/).7% (7/955).8% (8/19) 1.7% (2/116) 2.4% (3/123).6% (6/153) 1.1% (12/186) 2.3% (2/87) 2.3% (2/87).6% (6/182) 1.2% (13/1122).3 mg ranibizumab.5 mg ranibizumab 5 15 Stroke Rate (%) Error bars = 95% CIs 42 7
8 /25 OS 1+ NS Clinical Case Dec 5, 12 Vision /1 Scheduled Jetrea April 3, 13 April 1, 13 Jetrea given April 11, 13 Vision /15 Kaleidoscope holes/tears with SD 36deg Vision /8 April 24, 13 Scleral depression Large horseshoe tear 4: with SRF Plan: vitrectomy/el/gfx/ilm peeling 8
9 Vitrectomy April 26, 13 May 18, 13 /7 Thrombogenics: ORBIT Ocriplasmin Research to Better Inform Treatment Phase 4 prospective clinical study to assess the realworld safety and effectiveness of ocriplasmin treatment for US patients with symptomatic vitreomacular adhesion (VMA) Aim is to collect real-time data on 15 patients at 1 US sites with up to one year follow up Enrollment to begin in early 14 Patient with exudative AMD Age-Related Macular Degeneration Diabetic Retinopathy Macular Edema Proliferative Disease 9
VMA at the macula resulting in VMT
Ocriplasmina for pharmacologic treatment in VMT Teresio Avitabile 1 Introduction PVD is a normal, physiologic process that occurs with aging; however, in some cases, PVD is incomplete Incomplete PVD localized
Early diagnosis and treatment of VMT with single Intravitreal Injection of Pharmacologic Vitreolysis. Stratos Gotzaridis MD Athens
Early diagnosis and treatment of VMT with single Intravitreal Injection of Pharmacologic Vitreolysis Stratos Gotzaridis MD Athens The Vitreous Body Gel composed of 98-99% water 1% macromolecules Glycoproteins
Treatment Options for VMT and Macular Holes Observation, Surgery, and Pharmacotherapy
Treatment Options for VMT and Macular Holes Observation, Surgery, and Pharmacotherapy Andrew Moshfeghi, MD, MBA Bascom Palmer Eye Institute Palm Beach Gardens, FL Financial Disclosures Salary/Honoraria:
Managing the Vitreomacular Interface
Managing the Vitreomacular Interface A Guide to VMA, VMT, Holes and ERM Anna K. Bedwell, OD, FAAO Indiana University School of Optometry Please silence all mobile devices and remove items from chairs so
Vitreo-retinal interface pathologies and fibrinolytic treatment approaches
Vitreo-retinal interface pathologies and fibrinolytic treatment approaches Constantin J. Pournaras Memorial A. de Rothschild Clinical Research Group La Colline Ophthalmology Center Vitreoretinal Interface
Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion/Traction. Baruch D Kuppermann, MD, PhD
Ocriplasmin for the Treatment of Symptomatic Vitreomacular Adhesion/Traction Baruch D Kuppermann, MD, PhD Professor of Ophthalmology and Biomedical Engineering; Chief, Service; Vice-Chair, Clinical Research,
Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Package. for. Ocriplasmin Intravitreal Injection, 2.5 mg/ml.
Food and Drug Administration Center for Drug Evaluation and Research Division of Transplant and Ophthalmology Products Dermatologic and Ophthalmic Drugs Advisory Committee Meeting Briefing Package for
Vitreomacular interface disorders. Ghanbari MD 1393:10:25
Vitreomacular interface disorders Ghanbari MD 1393:10:25 Human vitreous after dissection of the sclera, choroid, and retina. Lamellar structure of the posterior vitreous cortex (PVC) in the monkey. V =
EPIRETINAL MEMBRANE & VITREOMACULAR TRACTION
EPIRETINAL MEMBRANE & VITREOMACULAR TRACTION Management of ERM and VMT K.V.Chalam,MD,PhD,MBA,FACS Professor and Director of Retina Loma Linda Eye Institute Los Angeles, USA REVIEW ANATOMY The vitreous
Vitreomacular Traction: Management
Miscellaneous Refractive Surgery Vitreomacular Traction: Management Raji K. MS, DNB Raji K. MS, DNB, A.K. Upadhyay MS, S. Waikar MS, DNB, P. Tiwari MBBS Department of Ophthalmology, Command Hospital (WC)
CONTRAINDICATIONS None. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JETREA safely and effectively. See full prescribing information for JETREA JETREA (ocriplasmin) injection,
Often asymptomatic but can cause a reduction in BCVA and distortion of vision.
Christopher Wolfe, OD, FAAO, Dipl. ABO Epiretinal Membrane (ERM) and Vitreomacular Traction (VMT) Epiretinal membrane (macular pucker, cellophane maculopathy, premacular fibrosis) consists of a layer of
Molecular weight: 27.2 kda Chemical name: microplasmin; recombinant truncated human plasmin CAS Number:
PRODUCT INFORMATION JETREA (ocriplasmin 0.5 mg/0.2 ml) Concentrated Solution for Intravitreal Injection after Dilution NAME OF THE MEDICINE JETREA solution for injection The chemical structure of ocriplasmin
The Foundation WHAT IS THE RETINA? continued next page. RETINA HEALTH SERIES Facts from the ASRS
The Foundation American Society of Retina Specialists Committed to improving the quality of life of all people with retinal disease. Vitreomacular Traction Syndrome The vitreous humor is a transparent,
JETREA CARE Provides JETREA At No Cost
JETREA CARE Provides JETREA At No Cost to All Qualifying Patients Who Do Not Have Insurance JETREA CARE Patient Assistance Program Your Health Insurance Coverage No Insurance (Uninsured) Your Potential
Related Policies None
Medical Policy BCBSA Ref. Policy: 9.03.30 Last Review: 03/29/2018 Effective Date: 03/29/2018 Section: Other Related Policies None DISCLAIMER Our medical policies are designed for informational purposes
Ocriplasmin for Treatment of Vitreomacular Traction: An Update
Ophthalmol Ther (2016) 5:147 159 DOI 10.1007/s40123-016-0062-6 REVIEW Ocriplasmin for Treatment of Vitreomacular Traction: An Update Mohammed Ali Khan. Julia A. Haller Received: July 22, 2016 / Published
PROSPECTIVE THREE-DIMENSIONAL ANALYSIS OF STRUCTURE AND FUNCTION IN VITREOMACULAR ADHESION CURED BY PHARMACOLOGIC VITREOLYSIS
PROSPECTIVE THREE-DIMENSIONAL ANALYSIS OF STRUCTURE AND FUNCTION IN VITREOMACULAR ADHESION CURED BY PHARMACOLOGIC VITREOLYSIS Kevin R. Tozer, BS,* Wolfgang Fink, PhD, ** Alfredo A. Sadun, MD, PhD, FARVO,
PREDICTIVE FACTORS OF VISUAL OUTCOME FOR VITREOMACULAR TRACTION SYNDROME AFTER VITRECTOMY
PREDICTIVE FACTORS OF VISUAL OUTCOME FOR VITREOMACULAR TRACTION SYNDROME AFTER VITRECTOMY Downloaded from https://journals.lww.com/retinajournal by mv7bzw+nz2blpko//cqyhwu2mokppdiwuep6ir1molueskh0dp9rbmb7dum5a2/cp6zifirtq3zbawzt+95f/m61fycawpqbpe8y2wuyzwnns2gw3+gmrxei6x11wu+s
Progressive Symptomatic Retinal Detachment Complicating Retinoschisis. Initial Reporting Questionnaire
Progressive Symptomatic Retinal Detachment Complicating Retinoschisis In association with the British Ophthalmological Surveillance Unit Ethics ref: 13/NW/0037 Initial Reporting Questionnaire Case Definition:
Vitreomacular Traction
Supplement to March 2014 Rethink Vitreomacular Traction With articles by Pravin U. Dugel, MD Anselm Kampik, MD J. Sebag, MD, FACS, FRCOphth, FARVO Ramin Tadayoni, MD, PhD Sponsored by Alcon The articles
Audit of Macular Hole Surgery, Visual Outcome Prediction on OCT Appearance of Macular Hole
International Journal of Ophthalmology & Visual Science 2017; 2(4): 93-97 http://www.sciencepublishinggroup.com/j/ijovs doi: 10.11648/j.ijovs.20170204.13 Audit of Macular Hole Surgery, Visual Outcome Prediction
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT JETREA 0.5 mg/0.2 ml concentrate for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains
Foveal Red Spot, Macular Microhole and Foveal Photoreceptor Defect in the Era of High-Resolution Optical Coherence Tomography
1:15 PM Foveal Red Spot, Macular Microhole and Foveal Photoreceptor Defect in the Era of High-Resolution Optical Coherence Tomography Edward F. Hall, MD Steven J. Rose, MD Brian P. Connolly, MD Ernest
04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint
Retina Coding and Reimbursement 101 William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan Genentech Regeneron
CLINICAL COURSE OF VITREOMACULAR ADHESION MANAGED BY INITIAL OBSERVATION
CLINICAL COURSE OF VITREOMACULAR ADHESION MANAGED BY INITIAL OBSERVATION VISHAK J. JOHN, MD,* HARRY W. FLYNN, JR., MD,* WILLIAM E. SMIDDY, MD,* ADAM CARVER, MD, ROBERT LEONARD, MD, HOMAYOUN TABANDEH, MD,
PRODUCT MONOGRAPH. Pr JETREA. ocriplasmin solution for intravitreal injection. 2.5 mg/ml. Professed Standard. Ophthalmological
PRODUCT MONOGRAPH Pr JETREA ocriplasmin solution for intravitreal injection 2.5 mg/ml Professed Standard Ophthalmological Sponsor: ThromboGenics N.V. Gaston Geenslaan 1 B-3001 Leuven Belgium Submission
An A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department
An A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department Types of ERM Natural history OCT prognostic factors ERM with co-existing pathology
04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts
Documentation Do s and Don ts In The Retina Practice William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan
Gas for Vitreomacular Traction RCT (Protocol AG) Gas for Macular Hole Single-Arm Study (Protocol AH)
Gas for Vitreomacular Traction RCT (Protocol AG) Gas for Macular Hole Single-Arm Study (Protocol AH) Protocol AG Chair: Clement Chan, MD Protocol AH Chair: Calvin Mein, MD DRCR.net Protocol AG Randomized
Vision Preference Value Scale and Patient Preferences in Choosing Therapy for Symptomatic Vitreomacular Interface Abnormality
11:30 AM Vision Preference Value Scale and Patient Preferences in Choosing Therapy for Symptomatic Vitreomacular Interface Abnormality Adrienne W. Scott, MD Voraporn Chaikitmongkol, MD Sobha Sivaprasad,
Enzymatic Vitreolysis with Ocriplasmin for Vitreomacular Traction and Macular Holes
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Enzymatic Vitreolysis with for Vitreomacular Traction and Macular Holes Peter Stalmans, M.D., Ph.D., Matthew S. Benz, M.D., Arnd Gandorfer,
Outline. Outline. Vitreous Development & Anatomy OPT - 243
2010 OPT - 243 Vitreous Disorders & Vitreoretinal Disorders of the Posterior Pole I Leo Semes, OD, FAAO 100% 0% 0% 0% 0% Which of these gives the best resolution for studying vitreoretinal disorders of
Diabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
! Reichert, Alcon, Allergan, CZ & Zeavision. Uchino, E. et al. Arch Ophthalmol ! Vitreoschisis (split within the vitreous)! ERM!
Financial disclosure From Print to Practice: PVD a common process with potential for ocular morbidity! I have received lecture honoraria or serve on the advisory boards or speaker s bureaus of:! Reichert,
Advanced Vitreoretinal Techniques & Technology Symposium
14th ANNUAL Advanced Vitreoretinal Techniques & Technology Symposium JULY 25-27, 2014 SWISSÔTEL CHICAGO CHICAGO, IL CME ACCREDITATION AND CREDIT STATEMENT This activity has been planned and implemented
Office Based Practice. Vitreoretinal Disease & Surgery. Coding Fiesta Vitreoretinal Disease & Surgery September 23, 2017 ADULT RETINA
Vitreoretinal Disease & Surgery Coding Fest 2017 Vitreoretinal Surgery & Disease University of FL College of Medicine ADULT RETINA Medical Retina Surgical Retina Age Related Vascular Disease Vascular Disease
Yasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD
Microperimetric Evaluation of Brilliant Blue G- assisted Internal Limiting Membrane Peeling By Yasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD The internal
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD
Recalcitrant Diabetic Macular Oedema: Therapeutic Options
December 2007 A. Giridhar et al. - Recalcitrant DME 451 CONSULTATION S E C T I O N Recalcitrant Diabetic Macular Oedema: Therapeutic Options Dr. Cyrus M Shroff 1, Dr. N S Muralidhar 2, Dr. R Narayanan
Vanderbilt Eye Institute Clinical Trials
April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director
CORRELATION BETWEEN CENTRAL FOVEAL THICKNESS AND VISUAL ACUITY IN PATIENTS WITH IDIOPATHIC VITREOMACULAR TRACTION
CORRELATION BETWEEN CENTRAL FOVEAL THICKNESS AND VISUAL ACUITY IN PATIENTS WITH IDIOPATHIC VITREOMACULAR TRACTION MEHMET M. UZEL, MD, MEHMET CITIRIK, MD, CAGRI ILHAN, MD, KEMAL TEKIN, MD Purpose: To evaluate
The Wilmer Eye Institute s 34 th Annual Current Concepts in Ophthalmology March 13-17, 2017 Vail Marriott * Vail, Colorado
The Wilmer Eye Institute s 34 th Annual Current Concepts in Ophthalmology March 13-17, 2017 Vail Marriott * Vail, Colorado Tentative 1/23/17 PROGRAM MONDAY, MARCH 13, 2017 Morning Session 6:00-7:00 Registration
Venturi versus peristaltic pumps 33 vitrectomy dynamics 34 Fluorescein, vitreous staining 120
Subject Index Accurus 35, 83 Aflibercept, diabetic macular edema management 167, 168 Air-forced infusion, Stellaris PC 12, 13 Alcon Constellation, see Constellation system Autoclave sterilization lens
11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES
MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile
OCT Assessment of the Vitreoretinal Relationship in CSME
December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction
Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
Retina Grandrounds. Retinal Grand Rounds Exhibition of Common Entities
Retina Grandrounds Retinal Grand Rounds Exhibition of Common Entities Mohammad R Rafieetary, O.D. mrafieetary@charlesrteina.com Exhibitions 1) Choroidal Neovascular Membrane 2) Vitreomacular Interface
When to Refer to RETINA. Joseph M. Coney, MD February 17, 2017 Memphis, TN
When to Refer to RETINA Joseph M. Coney, MD February 17, 2017 Memphis, TN Financial Disclosure Commercial Interest What was received For what role Aerpio Grant Support Contracted Research Alcon Laboratories
Macular Hole Associated with Vogt-Koyanagi-Harada Disease at the Acute Uveitic Stage
Published online: September 15, 2015 2015 The Author(s) Published by S. Karger AG, Basel 1663 2699/15/0063 0328$39.50/0 This article is licensed under the Creative Commons Attribution-NonCommercial 4.0
Course # Getting to Know Your OCT
Course # 140 Getting to Know Your OCT Course Title: Lecturer: Getting to Know Your OCT Brad Sutton, OD, FAAO IU School of Optometry Financial Disclosures No financial disclosures Optical Coherence Tomography-OCT
Here s what you need to know about your treatment with JETREA (ocriplasmin)
Here s what you need to know about your treatment with JETREA (ocriplasmin) JETREA is used to treat adults with an eye disease called vitreomacular traction (VMT), including when it is associated with
Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
Disclosures. Objectives. Small gauge vitrectomy POD 1. The routine postoperative course 1/24/2018. None
Disclosures Retina Surgery: Postoperative Considerations and Complications None D. Wilkin Parke III, M.D. VitreoRetinal Surgery, PA 1 2 Objectives Small gauge vitrectomy To understand the common and serious
Early surgery preserves more vision for patients with Epiretinal Membranes
Early surgery preserves more vision for patients with Epiretinal Membranes Rahman R 1, Stephenson J 2 KEYWORDS: Epiretinal membrane, Combined phakovitrectomy, OCT. Addresses: 1 Ms Rubina Rahman*, CalderdaleRoyalHospital,
Anina Abraham, Consultant, Swarup Eye Centre, Hyderabad, India. The author has no financial interests
Reduced Incidence of Sclerotomy Related Breaks during 23-Gauge Vitrectomy Anina Abraham, Consultant, Swarup Eye Centre, Hyderabad, India The author has no financial interests Introduction Sclerotomy related
Moncef Khairallah, MD
Moncef Khairallah, MD Department of Ophthalmology, Fattouma Bourguiba University Hospital Faculty of Medicine, University of Monastir Monastir, Tunisia INTRODUCTION IU: anatomic form of uveitis involving
New Developments in the treatment of Diabetic Retinopathy
New Developments in the treatment of Diabetic Retinopathy B. Jeroen Klevering University Medical Centre Nijmegen - The Netherlands Topics Management of diabetic retinopathy Interventions a. primary (prevention)
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
Clinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
Columbia International Publishing Journal of Ophthalmic Research (2014) Research Article Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
Eccentric Macular Hole after Pars Plana Vitrectomy for Epiretinal Membrane Without Internal Limiting Membrane Peeling: A Case Report
Ophthalmol Ther (2017) 6:391 395 DOI 10.1007/s40123-017-0113-7 CASE REPORT Eccentric Macular Hole after Pars Plana Vitrectomy for Epiretinal Membrane Without Internal Limiting Membrane Peeling: A Case
Optometric Postoperative Cataract Surgery Management
Financial Disclosures Optometric Postoperative Cataract Surgery Management David Dinh, OD Oak Cliff Eye Clinic Dallas Eye Consultants March 10, 2015 Comanagement Joint cooperation between two or more specialists
OPTIC DISC PIT Pathogenesis and Management OPTIC DISC PIT
OPTIC DISC PIT Pathogenesis and Management Abdel-Latif Siam Ain Shams University Cairo Egypt OPTIC DISC PIT Congenital pit is an atypical coloboma usually located on the temporal edge of the disc, associated
Darren J. Bell, M.D. Texas A&M University College of Medicine College Station, Texas Doctor of Medicine
Darren J. Bell, M.D. Education Texas A&M University College of Medicine College Station, Texas Doctor of Medicine 1997-2001 Texas A&M University College Station, Texas Bachelor of Science, Biomedical Engineering
Barcelona, 3 4 June 2011 Auditorium IMO (Institut de Microcirurgia Ocular)
Trends in Surgical and Medical Retina Barcelona, 3 4 June 2011 Auditorium IMO (Institut de Microcirurgia Ocular) www.esaso.ch 1 Trends in Surgical and Medical Retina Trends in Surgical and Medical Retina
VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD
VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD VITREOMACULAR UPDATE FOR THE PRIMARY CARE OD 1 2 DISCLOSURE STATEMENT I have received lecture honoraria from TearScience. I have no direct financial or proprietary
Ophthalmic Imager Role
MASTER OCT Ophthalmic Photographers Society October 18, 2014 Chicago, IL James B Soque, CRA COA Pamela A Weber, MD Island Retina Shirley, New York Commack, New York Financial Disclosure Genentech Ophthotech
Advanced Vitreoretinal Techniques & Technology Symposium
15th ANNUAL Advanced Vitreoretinal Techniques & Technology Symposium AUGUST 28-30, 2015 SWISSÔTEL CHICAGO CHICAGO, IL CME ACCREDITATION AND CREDIT DESIGNATION This activity has been planned and implemented
CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
VITREOUS FLOATERS AND PHOTOPSIA AS PREDICTORS OF VITREORETINAL PATHOLOGY
Basrah Journal Of Surgery VITREOUS FLOATERS AND PHOTOPSIA AS PREDICTORS OF VITREORETINAL PATHOLOGY Salah Zuhair Al-Asadi MB,ChB, FRCS, FIBMS, Lecturer of Ophthalmology, College of Medicine, University
I need to acknowledge Dr. Inder Paul Singh for providing slides for this presentation
I need to acknowledge Dr. Inder Paul Singh for providing slides for this presentation DISCLOSURES I AM A: CONSULTANT TO ELLEX SPEAKER FOR ELLEX RESEARCH FOR ELLEX It s a really good laser for capsulotomies
Low Illumination 3-D Heads-Up Vitrectomy for Diabetic Macular Edema
Low Illumination 3-D Heads-Up Vitrectomy for Diabetic Macular Edema Yoshihiro Yonekawa, M.D., Bozho Todorich, M.D., Ph.D., Jeremy D. Wolfe, M.D. Yoshihiro Yonekawa, M.D., is a vitreoretinal surgeon at
Case report 12/10/2014. Delphine Lam ; Dr Mayer Srour Service d ophtalmologie Professeur E.Souied Université Paris Est
Case report 12/10/2014 Delphine Lam ; Dr Mayer Srour Service d ophtalmologie Professeur E.Souied Medical history Man, 75 years old Complaint: Vision loss in left eye in June 2014 Past ophthalmologic history:
Royal Berkshire Hospital Dunedin Hospital. Prince Charles Eye Unit Pi Princess Margaret Hospital
Vitreoretinal Surgery Mr Vaughan Tanner www.tanner-eyes.co.uk eyes Reading Royal Berkshire Hospital Dunedin Hospital Windsor Prince Charles Eye Unit Pi Princess Margaret Hospital Success rates VR surgery
History/principles of the OCT What does the normal retinal OCT look like Vitreal disorders Retinal/RPE disorders Choroidal disorders
Nathan Lighthizer, O.D., F.A.A.O. Assistant Professor Assistant Dean for Clinical Care Director of Continuing Education Chief of Specialty Care Clinics Chief of Electrodiagnostics Clinic Oklahoma College
CLINICAL SCIENCES. Surgery for Idiopathic Full-Thickness Macular Hole
CLINICAL SCIENCES Surgery for Idiopathic Full-Thickness Macular Hole Two-Year Results of a Randomized Clinical Trial Comparing Natural History,, and Autologous Serum: Moorfields Macular Hole Study Report
A retrospective nonrandomized study was conducted at 3
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,
Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology, diagnosis, and treatment
OPEN (2013) 27, S1 S21 & 2013 Macmillan Publishers Limited All rights reserved 0950-222X/13 www.nature.com/eye Idiopathic vitreomacular traction and macular hole: a comprehensive review of pathophysiology,
Ocriplasmin Efficacy An Analysis of Real-world Results from 2013 to Baruch D Kuppermann
Ocriplasmin Efficacy An Analysis of Real-world Results from 2013 to 2015 Baruch D Kuppermann Professor of Ophthalmology and Biomedical Engineering; Chief, Retina Service; Vice Chair, Academic Affairs,
Optical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP
Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features
Scleral buckling. Surgical Treatment
Dr. Ayman M. Khattab MD, FRCS professor of Ophthalmology Cairo University Surgical Treatment Pneumatic retinopexy. Primary pars plana vitrectomy. 1 Indications for scleral buckling. SB is used to treat
Review Article Spectral Domain Optical Coherence Tomography in the Diagnosis and Management of Vitreoretinal Interface Pathologies
Hindawi Publishing Corporation Volume 2012, Article ID 876472, 7 pages doi:10.1155/2012/876472 Review Article Spectral Domain Optical Coherence Tomography in the Diagnosis and Management of Vitreoretinal
ThromboGenics Business Update Q1 2018
Press release 9 May 2018 Regulated Information ThromboGenics Business Update Q1 2018 Advancing Diabetic Eye Disease Portfolio Positive Initial Topline Data from Phase 1/ 2a Clinical Study evaluating THR-
Visual and Anatomical Outcomes of Vitreous Surgery for Large Macular Holes
March 2009 Raju K.V. et al. - Closed Globe Injuries 31 ORIGINAL ARTICLE Visual and Anatomical Outcomes of Vitreous Surgery for Large Macular Holes Dr. Mahesh G. MS DO DNB FRCSEd, Dr. A. Giridhar MS, Dr.
RETINA TODAY Symptomatic Vitreomacular Adhesion
Supplement to July/August 2011 RETINA TODAY Symptomatic Vitreomacular Adhesion CME ACTIVITY Diagnosis, Pathologic Implications, and Management SYMPTOMATIC VITREOMACULAR ADHESION Release date: July 2011.
International Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
Financial Disclosures
Financial Disclosures DB is a scientific advisor for Regeneron/ Bayer and Genentech/ Roche & a DB member of the Regeneron Combination Products Steering Committee RCH receives grant support from Regeneron/
Consulting Fee: Alcon Laboratories
Consulting Fee: Alcon Laboratories Pre-Op EMM Post PPV, Forceps EMM & ILM Peeling 25/27 Gauge, Trans-Conjunctival, Sutureless PPV Inside-Out, End-Grasping Forceps Peeling w/ Alcon 25G End-Grasping DSP
SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES
SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES TABLE OF CONTENTS Summary Benchmarks for Preferred Practice Pattern Guidelines Introduction... 1 Glaucoma Primary Open-Angle Glaucoma (Initial
DIABETIC VITRECTOMY INDICATIONS AND TECHNIQUES. steve charles
DIABETIC VITRECTOMY INDICATIONS AND TECHNIQUES steve charles Traction Retinal Detachment Macula involved TRD TRD with rhegmatogenous component even if extra-macular TTRD Extra-Macular TRD should be observed
Steven Ferrucci, OD. FAAO; Jeffry Gerson, OD, FAAO; Robert Prouty, OD, FAAO; Leo semes OD, FAAO
PARDON THE OBJECTION: RETINA Steven Ferrucci, OD. FAAO; Jeffry Gerson, OD, FAAO; Robert Prouty, OD, FAAO; Leo semes OD, FAAO 1. Introductions/Disclosures (Ferrucci) 2. The genetics of AMD (Gerson) a. Background
Practical Care of the Cataract Patient with Retinal Disease
Practical Care of the Cataract Patient with Retinal Disease Brooks R. Alldredge, OD, FAAO Kelly L. Cyr, OD, FAAO The Retina Center Eye Associates of New Mexico 4411 The 25 Way NE, Suite 325 Albuquerque,
Ophthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
Macular Hole. Helpline
Macular Hole The retina is a light-sensitive layer of tissue lining the back of the eye. The macula is a small area at the centre of the retina responsible for all of our central vision, most of our colour
Diabetic eye disease. Diabetic retinopathy. Sam S. Dahr, M.D. Retina Center of Oklahoma.
Diabetic eye disease Sam S. Dahr, M.D. Retina Center of Oklahoma www.rcoklahoma.com Downloaded from: The Retina (on 28 May 2007 12:48 AM) 2007 Elsevier Diabetic retinopathy Downloaded from: The Retina
JANUARY 27-29, TH ANNUAL Retina Fellows Forum. Westin Chicago River North Chicago, IL
17TH ANNUAL Retina Fellows Forum JANUARY 27-29, 2017 Westin Chicago River North Chicago, IL Course Director: Course Co-Directors: and David R. Chow, MD Faculty Course Co-Director Tennessee Retina Nashville
R&M Solutions
Mohamed Hosny El-Bradey, MD., Assistant Professor of Ophthalmology, Tanta University. Wael El Haig, MD., Professor of Ophthalmology. Zagazeeg University. 1 Myopic CNV is considered the most common vision
3/6/2014. Hoda MH Mostafa MD Associate Professor of Ophthalmology Cairo University. The author has no proprietary interest. Today s Objectives
Hoda MH Mostafa MD Associate Professor of Ophthalmology Cairo University The author has no proprietary interest Today s Objectives Identify the CLINICAL SCENARIOS IN MACULAR EDEMA where OCT plays a MAJOR
Disclosures. How small?
Disclosures Still have not changed. Surgical Panel Sunil K. Srivastava, MD Cleveland, OH Lets get these few comments out of the way How small? Do you stain for ILM peels? And if so what do you use Do you